Introduction. Infection with cytomegalovirus (CMV) is considered the most common maternalfetal infection, which can cause serious repercussions on the fetus and is a significant threat to public health. Material and methods. Cross-sectional descriptive study of 51 patients with symptomatic congenital infection with CMV, hospitalized in the Municipal Clinical Children Hospital of Contagious Diseases (SCMBCC), during 20212023, treated with Valgancyclovir. Results. Average age of the research group - 6.5 ±2.2 months, 45.1% girls and 54.9% boys, including 27.5% premature. Valgancyclovir was indicated taking into account the clinical manifestations, but also the viral load detected by PCR in blood and urine (viremia mean values 6,133.5 copies/ml, viruria – 5,545,642 copies /ml). Valgancyclovir indicated in a dose of 16 mg/kg per bone, every 12 hours. In 11 patients (21.6%), the dose was halved (8 mg/kg, every 12 hours), taking into account the development of neutropenia (7 patients) or thrombocytopenia and/ or increased serum transaminase values (4 patients). Antiviral treatment lasted an average of 2.7 ±0.75 months. In all cases clinical parameters improved. CMV DNA negativity in plasma after 30 days of treatment – in 47 children (92.2%), in urine in 30 (58.8%), and on the 90th day - in plasma in 50 (98.1%) , and urine - in 48 (94.2%) children. Conclusion. Treatment with Valganciclovir in congenital CMV proved to be effective, presenting important pay-off in eliminating CMV DNA in blood and urine. Adverse effects were reported in about 1/5 of the cases, but were easily overcome by reducing the administered dose.